US biotech company Myriad Genetics is facing claims that 14 of its patents covering tests for breast and ovarian cancer are invalid and non-infringed by Quest Diagnostics.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
myriad genetics, quest diagnostics, brca1, brca2, aclu
